Structural Heart > TAVI Portfolio > ACURATE neo2 Aortic Valve System > Coronary Access

Today's TAVI requires easy coronary access.


With TAVI treatment expanding to increasingly younger patient populations, preserving coronary access has become more critical than ever.

 
 

Up to 75% of TAVI patients
have coronary artery disease1


0% coronary obstruction demonstrated
by ACURATE™ platform*, 1, 2

Future Treatment Options Open

Keeping Future Treatment Options Open

ACURATE neo2's unique design provides coronary clearance and preserves access where others may not - even in low coronary ostia (≥ 8mm)†1

Angio image
  Watch Video  
 
 
 

ACURATE neo2: Designed to preserve
future coronary access

 

ACURATE neo2™ product image
 

Extra-Wide Stabilization Arches

Stable deployment for future interventions
Extra-wide stabilization arches

Supra-annular leaflets free from stent frame

Valve leaflets are not encapsulated behind a stent frame, minimizing the risk of caging the aortic root
Supra-annular leaflets free from stent frame

Upper-crown caps native leaflets

 
 
 
 

The RE-ACCESS Study‡,1

Coronary Cannulation After TAVR

ACURATE neo: the only supra-annular valve platform demonstrating 100% successful coronary cannulation.

ACURATE neo valve platform

demonstrated

100%

successful coronary
cannulation

Evolut R/PRO

demonstrated

82%

successful coronary
cannulation


SAPIEN

demonstrated

99%

successful coronary
cannulation


 
 
 

View

full RE-ACCESS study results.
  View Now  
Top